{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:56:00Z","timestamp":1791352560588,"version":"4.3.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T00:00:00Z","timestamp":1393977600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090795","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T21:43:52Z","timestamp":1394055832000},"page":"e90795","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models"],"prefix":"10.1371","volume":"9","author":[{"given":"B\u00e9reng\u00e8re","family":"Gobin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatien","family":"Moriceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Redini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1138\/20110531","article-title":"Bone sarcomas: pathogenesis and new therapeutic approaches","volume":"8","author":"D Heymann","year":"2011","journal-title":"IBMS BoneKey"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3","article-title":"Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenicsarcoma","volume":"37","author":"G Rosen","year":"1976","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, <etal>et al<\/etal>. (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 704872.","DOI":"10.1155\/2012\/704872"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cancers5020591","article-title":"Current Therapeutic Strategies and Novel Approaches in Osteosarcoma","volume":"5","author":"K Ando","year":"2013","journal-title":"Cancers"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.26336","article-title":"Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth","volume":"118","author":"G Moriceau","year":"2012","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","article-title":"Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas","volume":"30","author":"SP Chawla","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process","volume":"70","author":"G Moriceau","year":"2010","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-09-0816","article-title":"NVP-BEZ235 as a new therapeutic option for sarcomas","volume":"16","author":"MC Manara","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-08-1657","article-title":"Inhibition of src phosphorylation alters metastatic potential of osteosarco ma<italic>in vitro<\/italic> but not <italic>in vivo<\/italic>","volume":"15","author":"P Hingorani","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate-a new oral targeted therapy","volume":"346","author":"DG Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0959-8049(02)00836-5","article-title":"Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study","volume":"39","author":"J Verweij","year":"2003","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"I El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal-cell dependent mechanisms","volume":"22","author":"S O\u2019Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptor b by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro","volume":"40","author":"F Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"K Vandyke","year":"2010","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ijc.2910200118","article-title":"Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride","volume":"20","author":"B Klein","year":"1977","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0304-3835(02)00433-0","article-title":"Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation","volume":"188","author":"A Kamijo","year":"2002","journal-title":"Cancer Lett"},{"key":"ref19","first-page":"223","article-title":"Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL\/6J mouse osteosarcoma","volume":"16","author":"MJ Joliat","year":"2002","journal-title":"In Vivo"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1158\/0008-5472.CAN-06-4130","article-title":"Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the vicious cycle between tumour cell proliferation and bone resorption","volume":"67","author":"F Lamoureux","year":"2007","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets","volume":"110","author":"U Rix","year":"2007","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6807-9-7","article-title":"The structure of the leukaemia drug imatinib bound to human quinone reductase 2 (NQO2)","volume":"9","author":"JA Winger","year":"2009","journal-title":"BMC Struct Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.bmcl.2009.06.002","article-title":"The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian \u03b1-carbonic anhydrase isoforms","volume":"19","author":"S Parkkila","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2009.07.002","article-title":"Mechanisms of bone repair and regeneration","volume":"15","author":"F Deschaseaux","year":"2009","journal-title":"Trends Mol Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/stem.596","article-title":"Concise review: mesenchymal tumours: when stem cells go mad","volume":"29","author":"AB Mohseny","year":"2011","journal-title":"Stem Cells"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccr.2007.02.027","article-title":"Mesenchymal stem cell features of Ewing tumours","volume":"11","author":"F Tirode","year":"2007","journal-title":"Cancer Cell"},{"key":"ref27","first-page":"3584","article-title":"Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571","volume":"8","author":"EC McGary","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23437","article-title":"Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma","volume":"112","author":"T Kubo","year":"2008","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.21132","article-title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumours: a Children\u2019s Oncology Group study","volume":"50","author":"M Bond","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","article-title":"Activity-based kinase profiling of approved tyrosine kinase inhibitors","volume":"18","author":"D Kitagawa","year":"2013","journal-title":"Genes to Cells"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1023\/A:1027355610603","article-title":"Biological properties and gene expression associated with metastatic potential of human osteosarcoma","volume":"20","author":"T Nakano","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1038\/oncsis.2012.34","article-title":"Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines","volume":"1","author":"AN Rettew","year":"2012","journal-title":"Oncogenesis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/039463201302600117","article-title":"Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis","volume":"26","author":"Y Zhang","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2013.05.019","article-title":"Gas6\/Axl mediates tumour cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients","volume":"435","author":"J Han","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"ref35","first-page":"775","article-title":"C-kit expression in human osteosarcoma and in vitro assays","volume":"4","author":"LN Miiji","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2559.2010.03713.x","article-title":"De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway","volume":"57","author":"R Fritsche-Guenther","year":"2010","journal-title":"Histopathol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4161\/cam.20888","article-title":"Bone cell interactions through Eph\/ephrin: bone modeling, remodeling and associated diseases","volume":"6","author":"K Mstuo","year":"2012","journal-title":"Cell Adh Migr"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/bjc.2013.578","article-title":"Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery","volume":"109","author":"J Posthumadeboer","year":"2013","journal-title":"Br J Cancer"},{"key":"ref39","first-page":"115","article-title":"Dancing with the dead: Eph receptors and their kinase-null partners","volume":"89","author":"L Truitt","year":"2011","journal-title":"Biochem Cell Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4143\/crt.2012.44.3.202","article-title":"Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?","volume":"44","author":"JA Lee","year":"2012","journal-title":"Cancer Res Treat"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1471-2407-13-245","article-title":"IR\/IGF1R signaling as potential target for treatment of high-grade osteosarcoma","volume":"13","author":"ML Kuijjer","year":"2013","journal-title":"BMC Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrm2717","article-title":"Proximal events in Wnt signal transduction","volume":"10","author":"S Angers","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/156800908785699324","article-title":"Importance of Wnt signaling in the tumour stroma microenvironment","volume":"8","author":"ML Macheda","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1586\/era.11.94","article-title":"The Wnt signaling pathway: implications for therapy in osteosarcoma","volume":"11","author":"P McQueen","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.22203\/eCM.v022a07","article-title":"Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores","volume":"22","author":"S Lavenus","year":"2011","journal-title":"Eur Cell Mater"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T05:23:28Z","timestamp":1565241808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090795"}},"subtitle":[],"editor":[{"given":"Gerard Roel","family":"Rutteman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090795","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]}}}